Australia is carefully awaiting the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, https://inessnsz297473.westexwiki.com/2528701/novo_nordisk_s_retatrutide_australia_a_new_hope_for_losing_weight